ANIMI-3

The only prescription product of its kind, Animi-3 contains a
combination of three important B vitamins - prescription strength Folic Acid, plus Vitamins B6 and B12 -Phytosterols, and pharmaceutical grade, DHA dominant omega-3 fatty acids. The omega-3 in Animi-3 has been highly refined to remove contaminants commonly found in fish oils such as methylmercury and PCB's.

As part of a well-balanced diet that is low in saturated fat and cholesterol,
Folic Acid, Vitamin B6 and Vitamin B12 may reduce the risk of vascular disease.
The FDA evaluated the above claim and found that, while it is known that diets low in saturated fat and cholesterol reduce the risk of heart disease and other vascular diseases, the evidence in support of the above claim is inconclusive.

In addition, consumption of omega-3 fatty acids may reduce the risk of coronary heart disease. The FDA evaluated the data and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive.

For more information on DHA and B vitamins, visit www.dhaandbvitamins.org.

Which Came First, the Disease or the Deficiency?

Studies published in peer-reviewed journals have reported that patients with cardiovascular disease, diabetes,rheumatoid arthritis, and depression may be deficient in vital nutrients:

-Omega-3 (DHA & EPA)
-Folic acid
-Vitamin B6 and B12
-Phytosterols

Addressing these deficiencies may reduce cardiovascular risk.*

Introducing Animi-3 Rx

Animi-3 is a prescription-only product with specially formulated
and highly refined omega-3 fatty acids. Animi-3 also contains the
B vitamins: folic acid, B6, and B12.

The omega-3 (DHA & EPA) in Animi-3 has beenhighly refined to
remove contaminants commonly found in fish oils such as

500 mg Omega-3  - 350 mg DHA  - 35 mg EPA  1 mg Folic Acid   12.5 mg B6 500 mcg B12 200 mg Phytosterols

Animi-3 capsules are indicated for nutritional support and folic acid supplementation and provide assurance of dosing control for these vital nutrients.

Clinical evidence presented by leading researchers at Cornell University suggests that the combination of ingredients such as in Animi-3 can be a valuable addition to the physician's therapeutic regimen.

New Animi-3 Clinical Trial

PBM Pharmaceuticals, the maker of Animi-3, is conducting a new study for cardiovascular
risk reduction and dementia by a leading heart disease specialist. The Animi-3 clinical study is a six-month, double-blind, randomized, placebo-controlled trial in 75 subjects ages 55-80 years with no prior history of dementia.

The study started in September 2005 and is being conducted by Ernst J. Schaefer, M.D.,
of Cardiovascular Research Associates, in Boston, MA. Dr. Schaefer is also a Professor of Medicine at Tufts University School of Medicine.

Back to Top

Animi-3 Links

Official Web Site
http://www.animi-3.com

Studies Involving DHA
Importance of Omega-3 Fatty Acids in Health and Disease
Plasma Fatty Acid Composition and Depression Are Associated in the Elderly: The Rotterdam Study
Consumption of Fish and Omega-3 Fatty Acids and Risk of Incident Alzheimer Disease
Health Benefits Of Docosahexaenoic Acid (DHA)
Omega-3 Fatty Acid Treatment of Women With Borderline Personality Disorder
Fish Consumption and the 30-Year Risk of Fatal Myocardial Infarction
Blood Levels of Long-Chain Omega-3 Fatty Acids and the Risk of Sudden Death
Decreased Rate of Coronary Restenosis after Lowering of Plasma Homocysteine Levels
The Effect of Dietary Omega-3 Fatty Acids on Coronary Atherosclerosis
Serum Folate and Risk of Fatal Coronary Heart Disease
Homocysteine and Cardiovascular Disease

Back to Top

----------------------------------------------------------------------------------------------------------------------------------------------------

1 "Increased Consumption of Omega-3 Fatty Acids May Lower the Risk of Cardiovascular Disease, Dementia, and Inflammatory Disease" Conference, July 1, 2004. Supported by PBM educational grant.

* FDA "Qualified Health Claims: B vitamins & Vascular Disease. As part of a well-balanced diet that is low in saturated fat and cholesterol, Folic Acid, Vitamin B6 and Vitamin B12 may reduce the risk of vascular disease. FDA evaluated the above claim and found that, while it is known that diets low in saturated fat and cholesterol reduce the risk of heart disease and other vascular diseases, the evidence in support of the above claim is inconclusive. Docket No. 99P-3029

FDA "Qualified Health Claims" Omega-3 Fatty Acids & Coronary Heart Disease. Consumption of omega-3 fatty acids may reduce the risk of coronary heart disease. FDA evaluated the above claim and determined that, although there is scientific evidence supporting the claim, the evidence is not conclusive. Docket No. 9IN-0103